Clinical and Genomic Responses to Open Heart Surgery

Phase 3

Completed

• Conditions: Ischemia-reperfusion (IR) Injury
• Interventions: Procedure: SHAM; Procedure: Remote ischemic preconditioning (RIPC)

• Registration Number: NCT00650507
• Lead Sponsor: The Hospital for Sick Children

Brief Summary

This study will be the first large scale randomized study of remote ischemic preconditioning (RIPC) ever performed and will define the role of this novel therapy as a clinical tool. This study will also be the first to define preoperative gene expression profiles associated with poor postoperative outcomes in a control (SHAM) population of children undergoing cardiac surgery. Finally, the role of RIPC in modifying these gene expression profiles will be examined. Therefore, mechanistic insight into the proven ability of RIPC to improve markers of tissue injury, and the expected improvement in clinically relevant endpoints, will be examined.

Detailed Description

Remote ischemic preconditioning (RIPC) is a powerful, innate mechanism of protection against ischemia-reperfusion (IR) injury. During the course of previous investigations, it was shown in animal models that transient limb ischemia (our stimulus for generating remote ischemic preconditioning) leads to induction of a portfolio of myocardial genomic responses concerned with stress-response and repair mechanisms, reduces myocardial infarction after prolonged coronary occlusion, protects against cardiopulmonary bypass-induced neural, pulmonary and myocardial damage, and when administered to the recipient, reduces IR injury in the transplanted heart.

In humans, it has been have shown that RIPC downregulates genes responsible for pro-inflammatory pathways concerned with TNFα-signaling, apoptosis and exocytosis in circulating leukocytes, reduces ischemia-induced endothelial dysfunction, and decreases markers of myocardial and lung injury in a pilot study of children undergoing open heart surgery. However, the latter study was not powered to demonstrate differences in anatomic and age-related subgroups, or clinically relevant 'hard' end-points such as ventilation time, intensive care, and length of hospital stay.

Thus, we are now proposing a large-scale clinical study examining genetic predictors of clinically relevant postoperative outcomes, and how they are modified by remote preconditioning.

Study Timeline

• Study Start: 2008-03
• Study First Submitted: 2008-03-27
• Study First Submitted QC: 2008-03-27
• Study First Posted: 2008-04-01
• Primary Completion: 2012-12
• Study Completion: 2012-12
• Status Verified: 2013-08
• Last Update Submitted: 2013-08-25
• Last Update Posted: 2013-08-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Subject age birth (>36 weeks gestation) to 17 years.
• Underlying cardiac anatomy and planned primary repair with no anticipated residual shunting. Repair must necessitate use of cardiopulmonary bypass.
• Informed consent/assent of subject, parent(s) or legal guardian as appropriate.

Exclusion Criteria

• Current or recent ischemic insult, defined as vascular occlusion or episode of cardiorespiratory collapse requiring medical intervention occurring within 7 days of enrollment.
• Evidence in any system for organ dysfunction that requires medical intervention.
• Current treatment with systemic anticoagulation therapy or the presence of a bleeding diathesis.
• Presence of important pulmonary or airway disease requiring medical intervention.
• Current or previous (within 10 days of screening) use of systemic corticosteroids.
• Recent (within 7 days of screening) or current documented systemic infection or sepsis.
• Anticipated unavailability of an uninstrumented limb with no anatomic or physiologic abnormality precluding administration of RIPC stimulus using a standard blood pressure cuff.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	SHAM	-
1	Remote ischemic preconditioning (RIPC)	-

Primary Outcome Measures

Name	Time	Method
Impact of RIPC on length of hospital stay.	Assessed through post-operative hospitalization.

Secondary Outcome Measures

Name	Time	Method
Gene expression patterns associated with effects of RIPC.	Assessed and recorded during the first 24 hours after surgery.
Neurodevelopmental Outcomes (Age 2-6 years old at surgery)	Follow-up at 12-18 months post-surgery	Patients greater than two years of age at the time of surgery will be assessed using the Wechsler Preschool and Primary Scale of Intelligence-Revised, the Peabody Picture Vocabulary Test - IV and the Beery-Buktenica Developmental Test of Visual-Motor Integration, 5th Edition. Parents will complete questionnaires pertaining to their child's behavior and adaptive behavior; the parent version of the Child Behavior Checklist and the parent version of the Vineland Adaptive Behavior Scales - II.
Patterns of baseline gene expression predictive of the clinical and physiologic impact of cardiopulmonary bypass in children (SHAM group only).	Assessed and recorded during the first 24 hours after surgery.
Impact of RIPC on clinical and physiologic markers related to ischemia-reperfusion injury after cardiac surgery in children.	Assessed and recorded serially during the first 48 hours after surgery.
Neurodevelopmental Outcomes (Age < 2 years old at surgery)	Follow-up at 12-18 months post-surgery	Patients less than a two years of age at the time of surgery will return at 12 -18 months postoperative to be assessed using the BSID- III. During the same visit, parents will complete questionnaires pertaining to their child's behavior and adaptive behavior; the parent version of the Child Behavior Checklist and the parent version of the Vineland Adaptive Behavior Scales - II.

Trial Locations

Locations (1)

Brian W. McCrindle; 🇨🇦 Toronto, Ontario, Canada